Heslop HE - Search Results

1

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.

Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N. Grada Z, et al. Among authors: heslop he. Mol Ther Nucleic Acids. 2013 Jul 9;2(7):e105. doi: 10.1038/mtna.2013.32. Mol Ther Nucleic Acids. 2013. PMID: 23839099 Free PMC article.

2

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. Gottschalk S, et al. Among authors: heslop he. Blood. 2001 Feb 15;97(4):835-43. doi: 10.1182/blood.v97.4.835. Blood. 2001. PMID: 11159505 Free article.

3

Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.

Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM. Gahn B, et al. Among authors: heslop he. Int J Cancer. 2001 Sep 1;93(5):706-13. doi: 10.1002/ijc.1396. Int J Cancer. 2001. PMID: 11477583

4

Treatment of Epstein-Barr virus-associated malignancies with specific T cells.

Gottschalk S, Heslop HE, Roon CM. Gottschalk S, et al. Among authors: heslop he. Adv Cancer Res. 2002;84:175-201. doi: 10.1016/s0065-230x(02)84006-4. Adv Cancer Res. 2002. PMID: 11883527 Review.

5

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM. Gottschalk S, et al. Among authors: heslop he. Blood. 2003 Mar 1;101(5):1905-12. doi: 10.1182/blood-2002-05-1514. Epub 2002 Oct 31. Blood. 2003. PMID: 12411306 Free article.

6

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Heslop HE, et al. Cytotherapy. 2002;4(5):433-4. doi: 10.1080/146532402320776071. Cytotherapy. 2002. PMID: 12473214 Review. No abstract available.

7

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Sili U, et al. Among authors: heslop he. J Immunother. 2003 May-Jun;26(3):241-56. doi: 10.1097/00002371-200305000-00008. J Immunother. 2003. PMID: 12806278

8

Options for T-cell based therapies.

Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM. Heslop HE, et al. Vox Sang. 2004 Jul;87 Suppl 2:230-4. doi: 10.1111/j.1741-6892.2004.00494.x. Vox Sang. 2004. PMID: 15209923 Review. No abstract available.

9

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Bollard CM, et al. Among authors: heslop he. J Immunother. 2004 Jul-Aug;27(4):317-27. doi: 10.1097/00002371-200407000-00008. J Immunother. 2004. PMID: 15235393

10

Adoptive immunotherapy for EBV-associated malignancies.

Gottschalk S, Heslop HE, Rooney CM. Gottschalk S, et al. Among authors: heslop he. Leuk Lymphoma. 2005 Jan;46(1):1-10. doi: 10.1080/10428190400002202. Leuk Lymphoma. 2005. PMID: 15621775 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

424 results

Search Page

Filters